Search

Your search keyword '"Purine-Nucleoside Phosphorylase genetics"' showing total 526 results

Search Constraints

Start Over You searched for: Descriptor "Purine-Nucleoside Phosphorylase genetics" Remove constraint Descriptor: "Purine-Nucleoside Phosphorylase genetics"
526 results on '"Purine-Nucleoside Phosphorylase genetics"'

Search Results

151. Catalytic site conformations in human PNP by 19F-NMR and crystallography.

152. ANRIL: molecular mechanisms and implications in human health.

153. A study on the interaction of rhodamine B with methylthioadenosine phosphorylase protein sourced from an Antarctic soil metagenomic library.

154. The evolution of catalytic residues and enzyme mechanism within the bacterial nucleoside phosphorylase superfamily 1.

155. Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma.

156. Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state.

157. Homozygous deletions of cadherin genes in chondrosarcoma-an array comparative genomic hybridization study.

158. Lack of expression of MTAP in uncommon T-cell lymphomas.

159. T- and B-cell defects in a novel purine nucleoside phosphorylase mutation.

160. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

161. Cerebellar abnormalities in purine nucleoside phosphorylase deficient mice.

162. Structure-activity relationship of a cold-adapted purine nucleoside phosphorylase by site-directed mutagenesis.

163. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer.

164. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.

165. Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts.

166. New phosphate binding sites in the crystal structure of Escherichia coli purine nucleoside phosphorylase complexed with phosphate and formycin A.

167. Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

168. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

169. Structural basis of the substrate specificity of Bacillus cereus adenosine phosphorylase.

170. Improved synthesis of 2'-deoxyadenosine and 5-methyluridine by Escherichia coli using an auto-induction system.

171. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.

172. Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway.

173. An examination of an Antarctic soil metagenomic-derivate putative methylthioadenosine phosphorylase gene as a novel reporter gene for promoter trapping.

174. The rare fluorinated natural products and biotechnological prospects for fluorine enzymology.

175. High-temperature cultivation and 5' mRNA optimization are key factors for the efficient overexpression of thermostable Deinococcus geothermalis purine nucleoside phosphorylase in Escherichia coli.

176. Purine nucleoside phosphorylase deficiency with a novel PNP gene mutation: a first case report from India.

177. Purine nucleoside phosphorylase deficiency: a mutation update.

178. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.

179. Entropy-driven binding of picomolar transition state analogue inhibitors to human 5'-methylthioadenosine phosphorylase.

180. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma.

181. Unraveling the structural and functional differences between purine nucleoside phosphorylase and 5'-deoxy-5'-methylthioadenosine phosphorylase from the archaeon Pyrococcus furiosus.

182. Identification and characterization of two adenosine phosphorylase activities in Mycobacterium smegmatis.

183. Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.

184. Effects of purine nucleoside phosphorylase deficiency on thymocyte development.

185. Validation of the catalytic mechanism of Escherichia coli purine nucleoside phosphorylase by structural and kinetic studies.

186. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

187. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes.

188. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

189. 5'-methylthioadenosine nucleosidase from yellow lupine (Lupinus luteus): molecular characterization and mutational analysis.

190. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.

191. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.

192. Low-molecular-mass purine nucleoside phosphorylase: characterization and application in enzymatic synthesis of nucleoside antiviral drugs.

193. Cloning and characterization of purine nucleoside phosphorylase in Escherichia coli and subsequent ribavirin biosynthesis using immobilized recombinant cells.

194. Molecular cloning, overexpression, purification, crystallization and preliminary X-ray diffraction analysis of a purine nucleoside phosphorylase from Bacillus subtilis strain 168.

195. Arsenate and phosphate as nucleophiles at the transition states of human purine nucleoside phosphorylase.

196. QnAs with Vern L. Schramm. Interview by Prashant Nair.

197. Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.

198. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).

199. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.

200. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.

Catalog

Books, media, physical & digital resources